- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Eyenovia Collaborates With Senju Pharma For Potential Treatment For Chronic Dry Eye | - | RTTNews | ||
| Di | Eyenovia, Inc.: Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease | 1 | GlobeNewswire (USA) | ||
| 01.07. | EYENOVIA, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 28.06. | Eyenovia announces pricing of $5M registered direct offering | 2 | Seeking Alpha | ||
| 28.06. | Eyenovia, Inc.: Eyenovia Announces Pricing of $5M Registered Direct Offering | 3 | GlobeNewswire (USA) | ||
| 14.06. | EYENOVIA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.06. | EYENOVIA, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 16.05. | EYENOVIA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.05. | Earnings call: Eyenovia reports Q1 2024 results, focuses on product pipeline | 3 | Investing.com | ||
| 15.05. | Eyenovia GAAP EPS of -$0.23 | 1 | Seeking Alpha | ||
| 15.05. | EYENOVIA, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 26.04. | EYENOVIA, INC. - 10-K/A, Annual Report | 3 | SEC Filings | ||
| 25.04. | Eyenovia, Inc.: Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension | 290 | GlobeNewswire (Europe) | Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye) Also announces upcoming ARVO... ► Artikel lesen | |
| 09.04. | Eyenovia (EYEN) Down 18% on Disappointing Corporate Update | 9 | Zacks | ||
| 08.04. | EYENOVIA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.04. | Eyenovia, Inc.: Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities | 107 | GlobeNewswire (Europe) | Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024 and a potential NDA to the FDA in 2025Continuing... ► Artikel lesen | |
| 03.04. | Eyenovia, Inc.: Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings | 2 | GlobeNewswire (USA) | ||
| 19.03. | EYENOVIA, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.03. | Eyenovia Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
| 18.03. | Recap: Eyenovia Q4 Earnings | 3 | Benzinga.com |
Seite:
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASTRIA THERAPEUTICS | 11,300 | +2,73 % | Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress | Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two... ► Artikel lesen | |
| ROCKET LAB USA | 5,040 | +1,41 % | Mynaric AG: Mynaric Selected by Rocket Lab for Space Development Agency's Tranche 2 Transport Layer - Beta Program | Laser Communications Manufacturer Expands Customer RosterLOS ANGELES, CA / ACCESSWIRE / May 7, 2024 / Mynaric (NASDAQ:MYNA)(FRA:M0YN), a leading provider of industrialized, cost-effective and scalable... ► Artikel lesen | |
| BOIRON | 31,800 | 0,00 % | BOIRON: EVOLUTION OF GOVERNANCE | July 3rd, 2024
The Board of Directors of Laboratoires BOIRON, meeting today under the chairmanship of Thierry BOIRON, has enacted an evolution of the Group's governance.
In this context, Thierry... ► Artikel lesen | |
| HARROW | 24,440 | +0,87 % | Harrow, Inc.: Harrow to Attend 2024 ASRS Annual Meeting | Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual... ► Artikel lesen | |
| MEDICINOVA | 1,200 | -1,64 % | MediciNova, Inc.: MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 | LA JOLLA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| ESSA PHARMA | 5,300 | -2,21 % | ESSA Pharma Inc: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024 | Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC naïve to second generation antiandrogens... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,825 | +10,87 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Positive Topline Data for Anaphylm (epinephrine) Sublingual Film from Self-Administration Study | Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs)Final supportive study, the Oral Allergy Syndrome... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 1,240 | -1,59 % | Reviva Pharmaceuticals: Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension | - Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary... ► Artikel lesen | |
| CYANOTECH | 0,260 | 0,00 % | Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2024 | KAILUA KONA, Hawaii--(BUSINESS WIRE)--Cyanotech Corporation (OTCQB Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial... ► Artikel lesen | |
| CUMBERLAND PHARMACEUTICALS | 1,460 | 0,00 % | Cumberland Pharmaceuticals Inc.: Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update | NASHVILLE, TENN., May 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands... ► Artikel lesen | |
| SHINECO | 0,680 | 0,00 % | Shineco, Inc.: Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement | BEIJING, June 27, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices, announced today... ► Artikel lesen | |
| LYRA THERAPEUTICS | 0,306 | -0,97 % | Lyra Therapeutics, Inc. - 8-K, Current Report | ||
| BAYER | 27,465 | -0,24 % | Bayer-Aktie an DAX-Spitze: Charttechnisch spannend | Mit einem Plus von gut drei Prozent rangiert das Papier von Bayer zu Wochenbeginn an der Spitze im DAX. Neuigkeiten von Unternehmens- oder Analystenseite, die die recht deutlichen Kursaufschläge begründen... ► Artikel lesen | |
| MERCK KGAA | 159,50 | +2,70 % | Merck Aktie: Kursrückgang trotz positiver Prognosen | Die Merck-Aktie verzeichnete am Freitag einen leichten Rückgang im XETRA-Handel. Trotz eines anfänglichen Kurses von 150,90 EUR sank der Wert im Tagesverlauf um 0,4 Prozent auf 149,05 EUR. Das Handelsvolumen... ► Artikel lesen | |
| ELI LILLY | 738,30 | -0,43 % | Eli Lilly and Aktie: Durchbruch in China treibt Kurs an | Die Eli Lilly and Aktie verzeichnete am Freitag einen bemerkenswerten Aufschwung an der Wall Street, während der Gesamtmarkt unter Druck geriet. Der Pharmariese erhielt eine wegweisende Genehmigung... ► Artikel lesen |
EYENOVIA INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,440 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EYENOVIA INC finden Sie auf Wallstreet Online.
